This study is currently not recruiting participants.

RE-VERSE-AD 1321.3 A phase III case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with diabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures.

Study on Investigational Medication for Bleeding Reversal

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to test and investigation drug called idarucizumab to see if it is safe and will reverse the bleeding effect of dabigatran.

Detailed description of study

The purpose of this study is to test and investigation drug called idarucizumab to see if it is safe and will reverse the bleeding effect of dabigatran.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Uncontrolled bleeding
  • Age: 100 years or below
  • Gender: All

This study investigates a medication to see if it is safe and can reverse the bleeding effects caused by another medication. It focuses on understanding how well this investigational medication works in stopping bleeding.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor the effects on bleeding reversal.

  • Who can participate: Eligibility criteria include age range from 18 to 65 years, with key factors such as a history of medication-induced bleeding.
  • Study details: Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1411838656

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team